Analysis of chosen immunological parameters in pulmonary tuberculosis;Analiza wybranych parametrów immunologicznych w gruźlicy płuc

Polski Merkuriusz Lekarski

Volumn 16, Issue 92, 2004, Pages 123-127

  Dubaniewicz, Anna ^a,b   Sztaba Kania, Magdalena ^a   Hoppe, Anzelm ^a  

^a AM ^*  (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Immunoglobulins A, G, M, C3, C4, Fc and C3 receptors; Lymphocytes B; Monocytes; Tuberculosis

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C4; ETHAMBUTOL; FC RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; ISONIAZID; PYRAZINAMIDE; RIFAMYCIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MONOCYTE; NEPHELOMETRY;

ADULT; AGED; ANTIGEN-ANTIBODY COMPLEX; ANTITUBERCULAR AGENTS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; COMPLEMENT C3; COMPLEMENT C4; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MACROPHAGE-1 ANTIGEN; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, FC; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 1642272835     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bennett J.M. i wsp.: Recomended methods for cytological procedures in haematology. Clin. Lab. Haemat., 1985, 7, 55-74.
2. Bosio C.M., Gardner D., Elkins K.L.: Infection of B cell-defficient mice with CDC1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. J. Immunology. 2000, 164, 6417-25.
3. Boyum A.: Isolation of human blood monocytes with Nycodenz, a new Non-ionic Iodineted Gradient Medium. Scand. J. Immunol., 1983, 17, 429-436.
4. Dubaniewicz A., Sztaba-Kania M.: Kŗźa̧ce kompleksy immunologiczne i fragment C3 układu dopełniacza w surowicy chorych na gruźlicȩ płuc. Pol. Merk. Lek., 2002, 12, 491-95.
5. Flynn J.L., Chan J.: Immunology of tuberculosis. Ann. Rev. Immunol., 2001, 9, 93-129.
6. Gatner E., Anderson R.: An in vitro assessment of cellular and humoral immune function in pulmonary tuberculosis;correction of defective neutrophil motility by ascorbate, levamisole, metoprolol and pronalonol. Clin. Exp. Immunol., 1980, 40, 27-336.
7. Hsieh K.H., Cheng R.F.: Different responses of monocytes and active T Lymphocytes to in vitro challenge of purified protein derivative in patients with active tuberculosis and healthy tuberculin reactors. Ann. Alerg., 1981, 46, 159-63.
8. Humber D.P. i wsp.: Controlled double-blind study of the effect of Rifampin on humoral and cellular immune responses in patients with pulmonary tuberculosis and in tuberculosis contacts. Am. Rev. Respir. Dis., 1980, 122, 425-36.
9. Hussain R. i wsp.: PPD-specific IgG1 antibody subclass upregulate TNF α expression in PPD stimulated monocytes. Possible link with disease pathogenesis in tuberculosis. Clin. Exp. Immunol., 2000, 119, 449-455.
10. Imaz M.S., i wsp.: Evaluation of the diagnostic value of measuring IgG, IgM, and IgA antibodies to the recombinant 16-kDa antigen of Mycobacteriu tuberculosis in childhood tuberculosis. Int. J. Tuberc. Lung. Dis., 2001, 5, 1036-1043.
11. Johnsosn N.I. Mc i wsp.: Circulating immune complexes in tuberculosis. Thorax, 1981, 36, 610.
12. Jondal M.: Surface maricers on human T and B limfocytes. J. Exp. Med., 1972, 136, 207-215.
13. Jungi T.W., Hafner S.: Quantitative assessments of Fc receptor expression and function in vitro differentiation of human monocytes to macrophages. Immunology, 1986, 58, 131-137.
14. Kaplan M.H., Chase H.W.: Antibodies to mycobacteria in human tuberculosis. I. Development of antibodies before and after antimicrobial therapy. J. Infect. Dis., 1980, 6, 825-834.
15. Katz P., Goldstein R.A.: Immunoregulation in infection caused by Mycobacterium tuberculosis: the presence of suppres-sor monocytes and the alteration of subpopulations of T lymphocytes. J. Infect. Dis., 1979, 140, 1221.
16. Kaplan G., Gaudrnack G.: In vitro differentiation of human monocytes. Dfifferences in monocyte phenotypes induced by cultivation on glass or on collagen. J. Exp. Med., 1982, 56, 1101-1114.
17. Khomenko A.G. i wsp.: Effects of chemotherapy on the immunological characteristics of patients with primary destructive pulmonary tuberculosis. Bull. WHO, 1984, 65, 763-771.
18. Khomenko A.G. i wsp.: Tuberculosis in patients with various HLA phenotypes. Tubercle, 1990, 71, 187-92.
19. Klaus G.G.B.: Lymphocyte receptors, signals and cytokines at Newport Beach. Immunology Today, 1988, 6, 157-159.
20. Maekura R. i wsp.: Clinical evaluation of antituberculous glycolipd immunoglobulin G antibody assay for rapid serodiagnosis of pulmonary tuberculosis. J. Clin. Microbiol., 2001, 39, 3603-3608.
21. Melo M.D. i wsp.: Utilization of CD11b knockout mice to characterize the role of complement receptor 3 (CR3, CD11b/CD18) in the growth of Mycobacterium tuberculosis. Cell Immunol., 2000, 205, 13-23.
22. Morito T.: FC-rosette inhibition by hypocomplementaemic systemic lupus erythematosus sera. Am. Rheum. Dis., 1976, 35, 415-425.
23. Nagabhushanam V., Cheers C.: Non-major histocompatibility complex control of antibody isotype and Th1 versus Th2 cytokines during experimental infection of mice with Mycobacterium avium. Infect. Immun., 2001, 69, 1708-13.
24. Pant D.C. i wsp.: Possible role of mononuclear phagocytes in clearaance of immune complexes in pulmonary tuberculosis. Indian J. Pathol. Microbiol., 1995, 38, 3305-309.
25. Radhakrishnan V.V., Mathai A., Sundaram P.: Diagnostic significance of circulating immune complexes in patients with pulmonary tuberculosis. J. Med. Microbiol., 1992, 36, 128.
26. Raja A.: Characterization of mycobacterial antigens and antibodies in circulating immune complexes from pulmonary tuberculosis. J. Lab. Clin. Med., 1995, 125, 581.
27. Sai-Baba K.S. i wsp.: Complement activation in pulmonary tuberculosis. Tubercule, 1990, 71, 103-107.
28. Schlesinger L.S. i wsp.: Phagocytosis of Mycobacterium tuberculosis is mediated by human monocytes complement receptors. J. Immunol., 1990, 144, 2771.
29. Skvor J., Trmka L., Kugukorova Z.: Immunoprofile studies in patients with pulmonary tuberculosis. Scand. J. Dis., 1979, 60, 168-71.
30. Szczuka I. (red.): Tuberculosis and Lung Diseases in Poland in 1998. Bull National Tuberculosis Lung Diseases Research Institut, Warszawa 1999, 11-99.
31. Turner J. i wsp.: The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. Exp. Gerontol., 2001, 36, 537-45.
32. Uma Devi K.R. i wsp.: Specific and early detection of IgG, IgA, IgM antibodies to Mycobacterium tuberculosis 38kDa antigen in pulmonary tuberculosis. Tuberculosis, 2001, 81, 249-253.
33. Urlichs T., Kaufmann H.E.: Mycobacterial resistance and immunity. Front. Biosc., 2002, 7, 458-469.
34. Vismara D. i wsp.: Identification of a 35-kilodalton Mycobacterium tuberculosis protein containing B- and T-cell epitopes. Infect. Immun., 1990, 58, 248-251.
35. Zabaleta J. i wsp.: Diminished adherence and/or ingestion of virulent Mycobacterium tuberculosis by monocyte-derived macrophages from patients with tuberculosis. Clin Diag. Labor. Immunol., 1998, 5, 690-694.